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(2,800USD), non-fatal IS with total disability 6,280BRL (3,934USD), embolism
11,810BRL (7,398 USD), transient ischemic attack 1,808BRL (1,133USD), fatal intra-
cranial hemorrhage 15,572BRL (9,754USD), fatal hemorrhagic stroke (HE) 23,260BRL
(14,570USD), non-fatal HE without disability 2,812BRL (1,761USD), non-fatal HE
with moderate disability 4,470BRL (2,800USD), non-fatal HE with total disability
6,280BRL (3,934USD), fatal extracranial hemorrhage 1,018BRL (638USD), minor
bleed 19BRL (12USD), fatal acute myocardial infarction (AMI) 15,530BRL (9,728USD)
and non-fatal AMI 16,852BRL (10,556USD). CONCLUSIONS: Costs of events related
to AF were significant, which underscores the importance of preventing it. Further,
it is known that as the population ages the prevalence of events increases.
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OBJECTIVES: This study attempts to investigate the impact of national mass
screening program on health service utilizations and medical expenses.
METHODS: Main data is consisted of the subjects (12,449,964) eligible for 2002
screening program provided by the National Health Insurance who were born in
even year. To analyze the effect of screening in the case of hypertension, we ex-
cluded people who had any medical records of hypertension before 2002. After
sorting and random sampling 5%(564,443), we extracted the subjects’ medical pay-
ments for hypertension complications in 2007. The independent variable of inter-
est is whether screened or not, and the dependent variables are the incidence and
costs of hypertension complications. We compared the results obtained using in-
strumental variable methods with those from conventional logistic and linear re-
gression models. RESULTS: Conventional logistic and multiple regression models
suggest that the possibility of utilizing medical services is significantly higher in
no-screen group and the average medical cost of hypertension complications re-
duced by 5% in screen group at 10% significant level. However, the results esti-
mated using instrumental variable methods show different results. The screen
group has significantly lower possibility to use medical service (p0.05), but the
lower average costs in screen group is not significant any more. CONCLUSIONS:
The different results demonstrate that conventional regression approaches may
have limitations in making causal inference using non-experimental data. This
study shows that whether one gets medical screen or not affects the possibility of
hypertension complications occurring, however it doesn’t significantly relate to
average costs.
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OBJECTIVES: To describe current management of acute coronary syndrome (ACS)
patients undergoing percutaneous coronary intervention (PCI) over 12 months in
Greece. METHODS: Prospective observational study in ACS patients undergoing
PCI from September 2008 - April 2009, capturing current practices over 12 months.
RESULTS: Twenty-two sites enrolled 558 eligible patients: 351 patients had unsta-
ble angina or non-ST elevation myocardial infarction (UA/NSTEMI) and 207 ST-
elevation myocardial infarction (STEMI). Median age was 64 years (IQR 55-73) (UA/
NSTEMI) and 56 years (IQR 49-66) (STEMI). Almost all patients (96.4%) received
stents: 19% BMS only, 77.5% DES only and 3.5% both. 79% UA/NSTEMI and 86%
STEMI patients were admitted to hospital within 1 day from start of ACS symp-
toms, while 78% UA/NSTEMI and 89% STEMI patients received the first antiplatelet
loading dose (LD) in 1 day. Time from start of ACS symptoms to PCI was 3 days in
76% UA/NSTEMI and 1 day in 67% STEMI patients. Follow-up data were available
for 540 (96.8%) patients. Percentage of patients on antiplatelets and other medica-
tions at hospital discharge and 12 months were as follows: aspirin 98%, 97%; clopi-
dogrel 99%, 96%; statins 81%, 79%; beta-blockers 73%, 72%; calcium blockers 11%,
11%; angiotensin II receptor blockers/angiotensin-converting enzyme inhibitors
64%, 62%; proton pump inhibitors 39%, 35%. A formal diet program was followed by
7% patients and a formal exercise program by 6% through the 1st year of follow up.
CONCLUSIONS: In ACS patients treated with PCI in Greece, dual antiplatelet treat-
ment is maintained in a very high percentage through one year post procedure, and
DES use is also high.
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A REVIEW OF THE PRIMARY CARE PRESCRIBING OF DABIGATRAN ETEXILATE
AND RIVAROXABAN IN IRELAND
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National Centre for Pharmacoeconomics, Dublin, Ireland Background: In Ireland, the National
Centre for Pharmacoeconomics, in collaboration with the Health Service Executive (HSE),
considers the cost-effectiveness of all new medicines following an application for reimbursement
under the community drugs schemes (CDS). The General Medical Services (GMS) scheme is the
largest of the CDS. In 2008, dabigatran etexilate (DBG) and rivaroxaban (RIV) received positive
reimbursement decisions for their licensed indication of venous thromboembolism (VTE)
prophylaxis in adults after total hip- and total knee-replacement.
OBJECTIVES: The objective was to analyse prescribing patterns of DBG and RIV on
the GMS scheme in Ireland in 2010.METHODS: A retrospective analysis of the GMS
prescribing database was performed. Analysis was performed using SAS (v9.1, SAS
Institute Inc. Cary, US). RESULTS: 1098 patients had received DBG. Of these, 37.34%
received it for longer than the maximum licensed duration of 35 days. Indeed,
15.94% received it for longer than 3 months and 7.56% for longer than 6 months.
1948 patients had received RIV. Of these, 25.77% had received it for longer than the
maximum licensed duration of 35 days. Indeed, 2.1% had received it for longer than
3 months and 0.36% for longer than 6 months. CONCLUSIONS: This indicates that
DBG and RIV may have been prescribed for unlicensed indications (for which pos-
itive reimbursement decisions have not yet been issued). Such indications include
stroke prevention in AF and VTE treatment. There are efficacy, safety and budget
impact concerns surrounding unlicensed prescribing. Also, should their licenses be
extended in the future, prescribing for such indications may increase regardless of
reimbursement decisions. There exists a need to introduce a policy in which drugs
are only reimbursed for those indications which have received positive reimburse-
ment decisions.
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OBJECTIVES: In 2007 the National Institute for Health and Clinical Excellence
(NICE) published national guidance for VTE prevention. Hospitals have been ex-
pected to implement these preventive measures, beginning with systematic pro-
cedures for risk assessment of inpatients. We measured the compliance with NICE
guidance in two hospitals in the South West of England two years after the publi-
cation of national guidance. METHODS: Systematic comparison of the implemen-
tation of national guidance on VTE prevention across two clinical specialities (gen-
eral medicine, orthopaedics) in two hospitals in 2009, using 200 randomly selected
longitudinal case studies, complemented by a qualitative study into their origins,
development and practical responses to national guidance. Based on the criteria
outlined in the NICE guidance we constructed a compliance score (minimum 0,
maximum 5). RESULTS: We found a mixed picture of compliance with national
VTE prevention guidance. Across both hospitals 90% of orthopaedic patients and
70% of general medical patients received VTE prophylaxis. In contrast, the pre-
scribed risk assessment was not systematically carried out or documented: only
68% of orthopaedic and 35% of medical patients were formally risk-assessed. Hos-
pital A achieved a compliance score of 1.28 (SD 0.76) in medicine and of 1.78 (SD
0.93) in orthopaedics. Hospital B achieved a score of 0.88 (SD 0.87) in medicine and
of 1.69 (SD 0.59) in orthopaedics. CONCLUSIONS: Despite clear national guidance
for VTE prevention, hospitals seem slow to implement, document or comply with
the recommendation of individual risk assessment to guide the need for prophy-
laxis. As shown by the high levels of VTE prophylaxis administration in both hos-
pitals and the qualitative interviews with senior clinicians, this is partially attrib-
utable to the fact that hospitals had strong internal guidance before the issue of
national guidance. The added value of documenting individual VTE risk assess-
ment is doubtful and limited compliance with national guidance is therefore not
surprising.
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OBJECTIVES: Current guidelines recommend antithrombotic therapy (oral antico-
agulant [OAC] or antiplatelet therapy [APT]) to prevent stroke in atrial fibrillation
(AF) patients in relation to stroke risk. Given the limitations of vitamin K antago-
nists [e.g., warfarin], OAC is often underused, and less effective APT is prescribed
instead or patients remain untreated. The objectives were: 1) To determine the type
of antithrombotic therapy used by AF patients as stratified by stroke risk (using
CHADS2 scores) in developed countries. 2) To assess quality of treatment with OAC
by time in therapeutic range (TTR) of international normalized ratios (INR).
METHODS: Studies were identified by literature review that reported 1) AF patients
and treatment level categorized by CHADS2 score and 2) TTR for AF patients.
RESULTS: In line with guidelines for AF treatment, as CHADS2 scores increased
(i.e., higher risk for stroke), the percentage of patients receiving OACAPT in-
creased and of patients receiving APT alone, or no treatment, decreased. A large
number of moderate to high risk patients (based on CHADS2 scores), however, were
still treated with AP alone (means: 25.6–37.6%; range 0–100%) or were untreated
(means: 4.4–10.6%; range:0.0–26.3%). Thus, up to 48% were treated inappropriately.
The reported proportion of treated patients with poor INR control ranged from
30-92% and varied according to TTR benchmark (50% to 75% TTR).
CONCLUSIONS:A large proportion of AF patients at moderate to high risk for stroke
are suboptimally treated. Among those who do receive OAC treatment, many are
poorly controlled and therefore receive little benefit. Using the CHA2DS2-VASc
score, a more recent risk assessment tool, would result in even higher numbers of
patients who are treated suboptimally. To prevent avoidable strokes among AF
patients, there is a need for safe and effective treatments that require less compli-
cated management (INR monitoring), therefore likely promoting higher compli-
ance and persistence.
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